Description

Accelerating Biomarker-Driven Drugs into Clinical Trials Whilst Strategising Your CDx Development, IVDR Compliance and Commercialisation Path to Improve Clinical Decision-Making and Patient Outcomes

The 13th Clinical Biomarkers and CDx Europe 2023 returns as the premier European forum for end-to-end discussions, actionable insights, and partnership development to guide biomarker discovery and companion diagnostics (CDx) development programmes as they progress toward commercialisation.

With two dedicated tracks on Biomarker Development and Drug-Dx Development and Commercialisation, this summit will be your ultimate guide to:

1) Understand European Biomarkers and CDx Development advancements in multiple disease areas in oncology and non-oncology indications
2) Discuss emerging functional assays and software technologies to advance and accelerate clinical and research programs aimed at personalising care for patients
3) Stay up to date with European specific regulatory, commercialisation and market access challenges and processes to successfully create your end-to-end biomarker and CDx strategy
4) Join forces to define a better framework for reimbursement of biomarkers that enable an equitable access to them for patients

Whether working in Oncology, NASH, Neuroscience, Inflammatory or cardiovascular diseases, come and join 250+ Clinical Biomarkers, Translational Medicine, Precision Medicine and Companion Diagnostics Directors, Heads and VPs together with biomarker and CDx solution providers, regulatory experts and notified bodies for a well-rounded, all stakeholders included learning and networking experience that you can’t afford to miss out.

 

URLs:
Website: https://go.evvnt.com/1502947-0?pid=10007
Brochure: https://go.evvnt.com/1502947-2?pid=10007

Prices:
Conference – Vendor and Solution Provider Pricing: GBP 3199.00,
Conference – Drug Developers and Academics: GBP 0.50

 

Speakers: Agata Baczynska, Head of Diagnostic Alliance Management, AstraZeneca, Alix Berton, VP, Head of Disease Understanding and Precision Biomarkers, Bayer, Anna Reznichenko, Senior Director, AstraZeneca, Anthony Hierholtzer, Associate Director, Clinical Biomarkers and Companion Diagnostics, Merck Group, Brian Baker, Senior Director – Regulatory Affairs and CDx, Regeneron Pharmaceuticals Inc, Brian Lockhart, Global Head of Companion Diagnostics, Servier, Clare Balendran, Vice President of Translational Development, Novo Nordisk, Dr. Sabine Fürst-Recktenwald, Principal Medical Director Personalised Health Care (PHC) Safety, Roche, Elizabeth Sheppard, Global Pricing and Market Access Director, Oncology Diagnostics, AstraZeneca, Fatima Bennai-Sanfourche, Senior Director of QA and RA Compliance for Medical devices, Combination products, and eHealth, Bayer, Francesca Cipolli, Associate Director, Precision Medicine and Digital Health, Global Regulatory Sciences, BMS, Geraldine Farjot, VP, Translational Medicine, Samsara Therapeutics, Helena Utkovic Westergren, Director, Precision Medicine Lead, AstraZeneca, Hugues Malonne, Director General, DG “Pre-authorization”, Federal Agency for Medicines and Health Products, Ian Kavanagh, Chief Operating Officer and Co-Founder, Apis Assay Technologies Ltd., James Hewitt, IVD Business Line Manager and Senior Specialist (CDx), TÜV SÜD, Joerg Engelbergs, Scientific-Regulatory Expert Targeted and Personalised Biomedicines, Paul-Ehrlich-Institute, John Smeraglia, VP Head of Global Integrated Bioanalysis, AstraZeneca, Julien Senac, Global Director, IVD Focus Team and Strategic Account Manager, TÜV SÜD, Lucian Visan, Head of Biomarkers and Translational Medicine, Imcyse, Lynn Durham, Chief Executive Officer and Founder, Stalicla S.A., Maciej Cabanski, Director Biomarkers and CDx, Monte Rosa Therapeutics, Michael Palmer, Vice President – Translational Oncology, Bicycle Therapeutics, Michael Zaiac, Head of Medical Affairs Oncology, Region Europe, Novartis AG, Nadia Viborg, Petersen Senior Scientist, Translational Immune Oncology, Evaxion Biotech, Pascal Forrer, Diagnostic Sciences Director (DxSD) in Hematology and CAR T cells, GDD Precision Medicine, Novartis AG, Patrick Fivey, Director, Precision Medicine Policy, AstraZeneca, Penny Wilson, Deputy Director, Innovative Devices, Medicines and Healthcare Products Regulatory Agency (MHRA), Philip Beer, Chief Scientific Officer, Step Pharma, Philippe Pinton, Senior Vice President, Head, Global Translational and Clinical Research and Development, Ferring International Center SA, Radha Krishnan, Executive Director, Clinical Pathology Lead, CDx, MSD, Richard Torstenson, Senior Director, Global Regulatory Affairs, AstraZeneca, Stephanie Traub, Associate Director, Bioanalytical Scientific Manager, Translational Biomarkers and Bioanalysis, UCB S.A., Stephen Lee, Director, Diagnostics Regulation, Association of British Healthcare Industries Ltd. – ABHI